A decision to sell more shares to the public this week didn't help bluebird bio's (NASDAQ: BLUE) sagging share price this year. The equity offering dilutes investors and throws cold water on hopes that an acquisition will happen soon. Nevertheless, bluebird bio remains on track to file for FDA approval of two gene therapy drugs in the next year, and trials for these drugs so far suggest they could be big successes.